2020
Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia
Wu C, Luedtke A, Sadikova E, Tsai H, Liao S, Liu C, Gau S, VanderWeele T, Kessler R. Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia. JAMA Network Open 2020, 3: e1921660. PMID: 32083693, PMCID: PMC7043195, DOI: 10.1001/jamanetworkopen.2019.21660.Peer-Reviewed Original ResearchConceptsFirst-episode schizophreniaAntipsychotic medicationPrescribed antipsychotic medicationTreatment success rateTreatment successSchizophrenic disordersFirst-episodeSuccess rateSchizophreniaProbability of treatment successTaiwan National Health Insurance Research DatabaseNational Health Insurance Research DatabaseHealth Insurance Research DatabaseEstimating treatment successValidation sampleIndividualized treatment rulesMedicationPrognostic studyPatientsInvestigated biomarkersClinical implementationDischarge diagnosisClinical observationsDemographic dataPragmatic trial
2018
Trajectories after first‐episode psychosis: Complement to ambiguous outcomes of long‐term antipsychotic treatment by exploring a few hidden cases
Liu C, Lin Y, Liu C, Hsieh M, Chien Y, Hwang T, Hwu H. Trajectories after first‐episode psychosis: Complement to ambiguous outcomes of long‐term antipsychotic treatment by exploring a few hidden cases. Early Intervention In Psychiatry 2018, 13: 895-901. PMID: 29927087, DOI: 10.1111/eip.12696.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisLong-term antipsychotic treatmentAntipsychotic treatmentRecurrence of psychotic symptomsCourse of chronic schizophreniaLow-dose antipsychoticsChronic schizophreniaDysthymic statesPsychotic symptomsDiagnostic stabilityWord lettersRemission criteriaPsychosisAmbiguous informationProbability of relapseCoping strategiesImpending relapseAmbiguous outcomesDiscontinued medicationAntipsychoticsPersonalized formulationsMedication adherencePsychosocial factorsEarly interventionGroup of patientsShared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia
Huang J, Liu C, Hwang T, Chen Y, Hsu Y, Hwu H, Lin Y, Hsieh M, Liu C, Chien Y, Tseng W. Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia. Human Brain Mapping 2018, 39: 2007-2019. PMID: 29377322, PMCID: PMC6866389, DOI: 10.1002/hbm.23982.Peer-Reviewed Original ResearchConceptsGeneralized fractional anisotropyGeneralized fractional anisotropy valuesAdequate antipsychotic treatmentNegative symptom scoresNonremission groupWhite matter tract integrityWhite matter integrityHealthy controlsRemission stateWhite matter tract bundlesWhite matter tractsReduced integrationAntipsychotic treatmentNonremitted patientsSchizophrenia patientsSymptomatic remissionIllness durationAnalysis of covarianceSchizophreniaDiffusion spectrum imagingTract integrityPost hoc analysisFractional anisotropyMedication dosesEducation years
2016
Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Garay R, Citrome L, Samalin L, Liu C, Thomsen M, Correll C, Hameg A, Llorca P. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion On Pharmacotherapy 2016, 17: 921-936. PMID: 26831200, DOI: 10.1517/14656566.2016.1149164.Peer-Reviewed Original ResearchConceptsCognitive impairment associated with schizophreniaSchizoaffective disorderNegative symptomsDopamine D2 receptor partial agonistTreatment of cognitive impairment associated with schizophreniaD2 receptor partial agonistTreating positive symptomsReceptor partial agonistEU clinical trial registriesAdd-on compoundsTardive dyskinesiaPositive symptomsGoal of recoverySchizophreniaPartial agonistAntipsychoticsSchizoaffectivePhase III of clinical developmentTherapeutic improvementDisordersClinical Trials RegistrySymptomsPharmacodynamic profileClinical developmentAcademic medical center
2013
Facial and Prosodic Emotion Recognition Deficits Associate with Specific Clusters of Psychotic Symptoms in Schizophrenia
Tseng H, Chen S, Liu C, Howes O, Huang Y, Hsieh M, Liu C, Shan J, Lin Y, Hwu H. Facial and Prosodic Emotion Recognition Deficits Associate with Specific Clusters of Psychotic Symptoms in Schizophrenia. PLOS ONE 2013, 8: e66571. PMID: 23818944, PMCID: PMC3688591, DOI: 10.1371/journal.pone.0066571.Peer-Reviewed Original ResearchConceptsEmotion recognition abilityCluster of psychotic symptomsPsychotic symptomsEmotion recognition taskHappy emotionHealthy participantsDysfunction of brain systemsSeverity of psychotic symptomsDeficits of emotion recognitionPresentation of psychotic symptomsDSM-IV diagnostic criteriaRecognition taskPANSS total scoreSensory modalitiesEmotion recognitionRecognition abilityEvaluation of symptomatologySeverity of clinical symptomsHappy prosodyNegative symptomsPerseveration errorsWAIS-IIIDSM-IVEmotional processingBrain systemsAripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis
Liu C, Chien Y, Hsieh M, Hwang T, Hwu H, Liu C. Aripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis. Journal Of Clinical Psychopharmacology 2013, 33: 18-23. PMID: 23277261, DOI: 10.1097/jcp.0b013e31827cb017.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisUltra-high riskFirst-episode psychosis patientsDrug-naiveUltra-high risk stateUltra-high-risk patientsLow-dose aripiprazoleNegative symptom scoresPositive symptom scoresFlexible dosing strategyState of psychosisTreatment responseAntipsychotic therapyDrug-naive populationSevere psychopathologyUHR patientsFirst-episodeAripiprazoleAdverse eventsSymptom scoresPsychosisRisk stateConcomitant medicationsTarget doseClinical improvement
2012
Zotepine-related myopathy in a patient with schizophrenia
Chen I, Hsieh M, Hwang T, Liu C. Zotepine-related myopathy in a patient with schizophrenia. European Journal Of Clinical Pharmacology 2012, 69: 725-726. PMID: 22797903, DOI: 10.1007/s00228-012-1346-y.Peer-Reviewed Original Research